. Antibody markers described in association with type 1 diabetes Thus, alternative explanations may be needed for at least some cases of diabetes. It is possible, for example, that a proportion of type 1 diabetes is not immune mediated, or that the immune response recognized as autoimmunity is a secondary, 'clearing up' operation after cell death caused by some other primary event, and of genetically determined intensity as we and others have arguedv-P. Alternatively, the insulin deficiency in such cases may result from islet cell dysfunction rather than destruction. Functional antibodies capable of stimulating and blocking gland function have been described in the thyroid ll • l 2 , and adrenal systems'", and recently in the islet system as well l4 • 15 • Immunoglobulin preparations from diabetic sera can block, sometimes entirely, the insulin response to glucose'".
What antibody markers are available in type 1 diabetes? A list of antibody markers described in association with type 1 diabetes is shown in Table 1 . Relatively little work has been carried out on islet cell surface antibodies, anti-albumin antibodies, anti-globulin antibodies and 'polar' antibodies. Only islet cell antibodies, the first to be described'P-!", have been studied in any depth for their value in predicting type 1 diabetes. Insulin autoantibodies have been extensively studied immunologically, but less so clinically. The 64K antibody is a promising current development'".
Islet cell antibodies (lCA) react with as yet unidentified cytoplasmic components of all islet cells, not just B cells, whereas islet cell surface antibodies are said to react with a membrane glycoprotein specific to B cells'". The 64K antibody also appears to be directed against a B cell specific antigen ( Anti-albumin antibody22 Anti-immunoglobulin antibody" 'Polar' antibody"
Antibody
Type 1 insulin-dependent diabetes mellitus (IDDM) is due to autoimmune disease of the pancreatic B cells. The insulitis leads to gradual destruction of the insulin secreting cells, islet cell failure and clinical diabetes. The prediabetic phase, which may last many years, is symptomless.
Whether this account is correct is important for two reasons. First, if clinical type 1 diabetes represents the complete and irreversible destruction of the functioning islet cell mass, only replacement treatment -that is, insulin -can be offered. Secondly, treatment in the prediabetic phase might be able to halt immune destruction. A number of prophylactic approaches have already been tried, some with modest success'. The rationale for antibody markers is to identify those at risk to whom such treatment might be given well in advance of clinical disease. The field is controversial, and this review will attempt to deal with some of the issues. Principal among them are the nature of the islet cell lesion which leads to insulin deficiency, the measurement of antibody markers, their behaviour and their predictive value.
Is autoimmune B cell failure always due to destruction?
This question is fundamentally important as the titre of antibody markers measured during the prediabetic period are generally thought to reflect the intensity of autoimmune destruction of the B cells. Antibodies are nevertheless products of the immune system, and not of the islets, so that the relationship between activity of the former and destruction of the latter deserves critical examination.
Chronic lymphocytic infiltration of the pancreatic islets reported in autopsy material obtained soon after the onset of clinical diabetes is viewed as the hallmark of autoimmune insulitis and the cause of insulin deficiency''. Insulitis and clinical diabetes can be induced by the adoptive transfer of lymphocytes from animal models of type 1 diabetes to healthy recipients", and in man, pancreas transplantation from healthy to diabetic homozygous twins results in early functional failure through insulitis, rather than rejection". Finally, immunomodulatory drugs such as cyclosporine A arrest the progression of insulitis but only for as long as they are administered', The evidence for immune-mediated islet cell destruction seems strong.
There are nevertheless many autopsy studies which report little or no evidence of insulitis 2 • 5 -7 • Insulitis was sometimes absent in serial pancreatic biopsies of spontaneously diabetic BB rats (Bone AJ, personal communication) and punch pancreatic biopsies in six humans at onset of IDDM recently showed a striking absence of insulin-containing islet cells but no evidence of lymphocytic infiltration''. mass 64 KDa)18. Insulin autoantibodies (IAA) react with a B cell specific product, insulin, but the remaining markers listed in Table 1 are antigenically less specific. The so-called polar antibody reacts with an antigen located near the polar surface ofRIN cells, a rat insulinoma cell line, but not with human B cells, and the basis for the reaction of IDDM sera with albumin and mixed globulins is less clear still.
A clear distinction should be made between association and prediction, though frequently it is not. There are numerous cross-sectional studies of correlation between the different antibody markers and disease groups, but very few in which sensitivity and specificity of the marker have been examined prospectively in an unselected population. The major reasons, of course, are the low incidence ofIDDM and the duration to onset, which may be several years.
Islet cell antibodies
Islet cell antibodies measured as ICA-IgG are detectable by indirect immunofluorescence in 70-80% of newly diagnosed type 1 diabetics and in 0.1-3% of the community'". However, only the highest titre ICA, corresponding to a complement-fixing subgroup (CF-ICA), predict diabetes; this has been a common source of confusion which the recent introduction of ICA standards, and a JDF (Juvenile Diabetes Foundation) unit, should help to resolve'". Thus ICA-IgG equivalent to < 20 JDF units are commonly found in the sera of IDDM relatives (10%) but have no predictive value for future diabetes. CF-ICAequivalent to > 40 JDF units, on the other hand, are substantially more predictive. Thus, in a recent report from the Barts-Windsor Family Study, 54% of24 CF-ICA positive subjects developed IDDM over an 8-year period, though only when the ICA was positive on three or more occasions'", A striking feature of ICA is their temporary character. In most patients the antibodies tend to disappear within a year of diabetes onset. In the more slowly progressive IDDM seen in adults, however, they may persist and can prove useful in differentiating adult type 1 from type 2 diabetes, and in predicting insulin dependency".
Although half the high titre ICA relatives in the Barts-Windsor study remained disease-free after 8 years, actuarial curves from this and the Joslin Family Study29 suggest a continuing trend towards clinical diabetes in such individuals. The King's College Twin Study, on the other hand, has identified a number of ICA positive twins who have remained discordant for so long that they are unlikely ever to develop diabetes'", Furthermore, a long-term followup of IDDM relatives in Seattle suggests that islet cell function may remain unchanged over 6 years or longer in ICA positive individuals, but can decline over a similar period in those who remain ICA negative", Although high titre ICA clearly mark for a high risk of future IDDM, the exceptions to the rule reduce their predictive value and need explanation if their true implications are to be understood.
Actuarial analysis is increasingly used in presenting data on the IDDM risk associated with ICA. Care in interpretation is important, however, as comparisons between groups (for example ICA + and ICA -) can sometimes look very favourable when correlation statistics are inappropriately applied. Actuarial curves relate to risk for the individual and should express either the relative risk with confidence limits, or the actuarial estimation of probability. As few Journal of the Royal Society of Medicine Volume 83 October 1990 633 individuals from even the largest studies develop diabetes, the margins for error (and hence the 95% confidence limits) can be very wide.
A further potential problem which applies to all such marker studies, whether ICA or other, is patient selection. Prospective studies are almost exclusively based on the siblings and other primary relatives of diabetics. However, fewer than 10% of diabetic families are multiplex", and it is not clear to what extent the data on familial diabetes applies to sporadic diabetes. Family members of a diabetic, particularly siblings, have a greater intrinsic chance of developing diabetes, irrespective of HLA phenotype, and the distribution of HLA phenotype is different among the diabetics of multiplex families than among those whose diabetes is sporadic'". A recent study has, nevertheless, examined virtually all the 0-14-year-olds (n=349) who became diabetic over a period of 12 months in Swederr'", Eighty-one per cent were ICA positive, although many had titres < 20 JDF units. The study is the first with evidence to suggest that the association between ICA and IDDM is as strong in sporadic as in familial IDDM.
The Gainesville group has also addressed the problem with a prospective community study of 5000 normal schoolchildren aged 6-14 years. ICA occurred in approximately 1 : 300, ie 17 of the children. Two with high titres have so far progressed to IDDM over 2-3 years of follow-up", More time must elapse before the predictive value of ICA in sporadic diabetes can be assured.
Their predictive value in high titre, but lack of any in low titre suggest that ICA are related in a graded manner to the intensity of whatever process leads to islet cell failure in IDDM. Perhaps ICA should be treated as a continuous variable in its predictive value for IDDM, rather than as present or absent. Islet cell antibodies in any event remain the best currently available marker for IDDM, their use mainly constrained by the need for human group 0 pancreas as a substrate and by considerable observer variation 26.
Insulin autoantibodies
Insulin autoantibodies (lAA) were first described in 18% of newly-diagnosed diabetic children in 1983 2°. The promise of a further marker for diabetes, against a known antigen and potentially straightforward to measure, has led to intensive investigation which has often raised more questions than it has answered. IAA are measured either by radiobinding (RBA) assay20,36 or by direct ELISA21,37. The RBA employs a minimum quantity of high specific activity ligand and is thereby affinity-sensitive in contrast to the antigen excess ELISA which is capacity sensitive". Whereas there is a large measure of concordance between the more experienced RBA and ELISA laboratories, international standardization workshops have nevertheless revealed systematic differences related to methodology'". The most recent recommendations are for the use of a human insulin ligand, competition/absorption steps to take account of nonspecific binding, and expression of results as standard deviation scores based on the signals from normal sera at test serum dilution.
IAA suffer the disadvantage that they are not IDDM specific. They occur, albeit rarely, in other autoimmune diseases-", insulin autoimmune syndrome''", and drug-induced autoimmunity".
The variable performance of laboratories measuring IAA and the systematic differences due to methodology together make the clinical literature on IAA particularly difficult to interpret. Thus, whereas some laboratories report associations between IAA and ICA and lAA and HLA, others do not. Another factor is variable patient selection. Unlike ICA, IAA vary in frequency and titre inversely with age, so that they are rarely detectable in adulthood. Karjalainen et at. recently reported on 82 children (ages 1.3-18.2 years) and 44 adults (20.0-55.8 years) studied at clinical onset of IDDM42. ICA were present in 81% of both groups, but IAA, while detected in 42.5% of the children, were present in only 3.8% of the adults. The Dusseldorf family study suggests that IAA are commoner in the primary relatives of multiplex diabetic families than of families where there is a single, sporadic, diabetic".
There is as yet little information from which to judge the predictive value of IAA for future IDDM. Early on, the Joslin group concluded that 'only a subset of ICA positive high risk subjects have autoimmunity towards the insulin molecule?", and later reported that there was no relationship between IAA and islet cell function as judged by the first phase insulin response to glucose", A report from the Barts-Windsor prospective study described a significant association between IgG (but not IgM) lAA and the subsequent development of IDDM, but only within the subgroup which was CF· ICA positivet", Nevertheless, nine of the 20 IAA positive subjects in this study were CF·ICA negative and unlikely to develop diabetes.
A small change in emphasis emerged when the Gainesville group reported a 'significantly increased likelihood of B cell dysfunction' when IAA were present in addition to ICA47. However, of the seven ICA positive subjects who progressed to clinical IDDM, only two were lAA positive. An Italian study suggested that the predictive value of CF-ICA for IDDM was raised from 65% to 76% by the co-existence of IAA, but patients with IAA alone did not develop diabetes'".
A further change in emphasis was the proposal that IAA may predict (inversely) the duration to diabetes onset, if a simple linear formula which incorporates early phase insulin release after intravenous glucose and IAA titre is used 49. lAA titres, however, rise steeply with decreasing age, and young diabetics have inevitably experienced a shorter prodrome. It is not yet clear whether IAA titres predict the duration of diabetes at all ages, or whether both lAA titre and duration of the prodrome are independent (and inverse) functions of age.
The consensus from what data are available would suggest that on their own, IAA have little predictive value for IDDM, but may improve on predictive value when found in association with high-titre ICA. A recent study has demonstrated different epitope restriction in lAA found in relation to diabetes compared with other clinical contexts'". Whatever their subtleties, however, IAA are currently detectable in fewer than 50% of diabetics, and this seriously limits their specificity,
The 64K antibody
Immunoprecipitated lysates of [35S] -methionine labelled islets were used by Baekkeskov et at. to identify antibodies in the sera of newly diagnosed diabetic children against a protein of64K Da relative molecular mass!", The technique was subsequently used to study prospectively the sera of 14 individuals aged 3-48 years who subsequently developed IDDM51. 64K antibodies were consistently detected in 11/14 IDDM patients, and in five first degree relatives, in two cases before ICA became detectable. The Gainesville group has reported the 64K antibody in 16 (80%) of 20 newly diagnosed IDDM subjects (compared with ICA in 75%)and in 20 (91%)of 22 'pre-IDDM' subjects, relatives ofIDDM patients with low first phase insulin responses.
Doubt, however, has been raised against the location of the 64K antigen on the surface of human islets 52, questioning its relevance as a target antigen in IDDM, though not necessarily its value as an antibody marker. A number of groups are currently attempting to clone the 64K antigen so as to provide unlimited material for the quantification of antibody in more manageable assays than the immunoprecipitation system currently available.
Conclusions
(l) Islet antibodies in high titre are currently the best marker for future IDDM, with high specificity but as yet unknown long-term sensitivity. The test is limited by the need for high resolution microscope optics, fresh frozen human pancreas and considerable experience in interpretation. The availability of a JDF standard and a universal system of units should improve the interlaboratory variance.
(2) A potentially important development is that of the 64K antibody identified as specific for the B cell and present in over 90% type 1 diabetics at onset. Cloning of the gene for the antigen will provide a source of pure protein for fully quantitative radiobinding or ELISA assays. (3) Insulin autoantibodies are present in fewer than 50% IDDM patients at onset, limiting their value as lone markers. They may improve the predictive value of ICA, but this is not a universal finding, and IAA occur in contexts other than IDDM, reducing their specificity. They are infrequent in diabetes presenting after puberty and even rarer in adults. (4) The new markers described during the last year or two -anti-polar antibodies, anti-albumin and anti-immunoglobulin antibodies -require further evaluation. (5) The role of antibody markers in type 1 diabetes depends critically upon the notion that those expressing such antibodies are subject to an inexorable decline in B cell function which ultimately leads to clinical diabetes. This notion of 'linearity' is a simple concept which has gained wide, sometimes uncritical, popularity. Exceptions in ongoing family studies, are nevertheless emerging which cast doubt on the inevitability of disease, so that caution is important in the interpretation of the literature. 
